Show simple item record

dc.contributor.authorO'NEILL, DESMONDen
dc.contributor.authorCOUGHLAN, TARAen
dc.contributor.authorCOLLINS, DANIELen
dc.contributor.authorMCCABE, DOMINICKen
dc.date.accessioned2015-01-22T09:44:09Z
dc.date.available2015-01-22T09:44:09Z
dc.date.issued2013en
dc.date.submitted2013en
dc.identifier.citationKinsella JA, Tobin WO, Cox D, Coughlan T, Collins R, O'Neill D, Murphy RP, McCabe DJ, Prevalence of Ex Vivo High On-treatment Platelet Reactivity on Antiplatelet Therapy after Transient Ischemic Attack or Ischemic Stroke on the PFA-100(®) and VerifyNow(®)., Journal of Stroke and Cerebrovascular diseases : the official journal of National Stroke Association, 22, 2013en
dc.identifier.issn1052-3057en
dc.identifier.otherYen
dc.identifier.urihttp://hdl.handle.net/2262/73111
dc.descriptionPUBLISHEDen
dc.description.abstractThe prevalence of ex vivo high on-treatment platelet reactivity (HTPR) to commonly prescribed antiplatelet regimens after transient ischemic attack (TIA) or ischemic stroke is uncertain. METHODS: Platelet function inhibition was simultaneously assessed with modified light transmission aggregometry (VerifyNow; Accumetrics Inc, San Diego, CA) and with a moderately high shear stress platelet function analyzer (PFA-100; Siemens Medical Solutions USA, Inc, Malvern, PA) in a pilot, cross-sectional study of TIA or ischemic stroke patients. Patients were assessed on aspirin-dipyridamole combination therapy (n = 51) or clopidogrel monotherapy (n = 25). RESULTS: On the VerifyNow, HTPR on aspirin was identified in 4 of 51 patients (8%) on aspirin-dipyridamole combination therapy (≥ 550 aspirin reaction units on the aspirin cartridge). Eleven of 25 (44%) patients had HTPR on clopidogrel (≥ 194 P2Y12 reaction units on the P2Y12 cartridge). On the PFA-100, 21 of 51 patients (41%) on aspirin-dipyridamole combination therapy had HTPR on the collagen-epinephrine (C-EPI) cartridge. Twenty-three of 25 patients (92%) on clopidogrel had HTPR on the collagen-adenosine diphosphate (C-ADP) cartridge. The proportion of patients with antiplatelet HTPR was lower on the VerifyNow than PFA-100 in patients on both regimens (P < .001). CONCLUSIONS: The prevalence of ex vivo antiplatelet HTPR after TIA or ischemic stroke is markedly influenced by the method used to assess platelet reactivity. The PFA-100 C-ADP cartridge is not sensitive at detecting the antiplatelet effects of clopidogrel ex vivo. Larger prospective studies with the VerifyNow and with the PFA-100 C-EPI and recently released Innovance PFA P2Y cartridges (Siemens Medical Solutions USA, Inc) in addition to newer tests of platelet function are warranted to assess whether platelet function monitoring predicts clinical outcome in ischemic cerebrovascular disease.en
dc.language.isoenen
dc.relation.ispartofseriesJournal of Stroke and Cerebrovascular diseases : the official journal of National Stroke Associationen
dc.relation.ispartofseries22en
dc.rightsYen
dc.subjectTransient ischemic attacken
dc.subjectplatelet functionen
dc.subjectischemic strokeen
dc.subjecthigh on-treatment platelet reactivityen
dc.subjectVerifyNowen
dc.subjectPFA-100en
dc.subjectAntiplatelet therapyen
dc.titlePrevalence of Ex Vivo High On-treatment Platelet Reactivity on Antiplatelet Therapy after Transient Ischemic Attack or Ischemic Stroke on the PFA-100(®) and VerifyNow(®).en
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/doneillen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/mccabedoen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/coughlten
dc.identifier.rssinternalid80768en
dc.identifier.doihttp://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2012.07.012en
dc.rights.ecaccessrightsopenAccess
dc.subject.TCDThemeAgeingen
dc.subject.TCDThemeNeuroscienceen
dc.identifier.orcid_id0000-0002-5542-9897en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record